



PAN MERSEY AREA PRESCRIBING COMMITTEE
PRESCRIBING POLICY STATEMENT
REF: PS136 FINAL
FIRST APC BOARD DATE: 12 JUN 2013
LAST APC BOARD DATE: 24 JUN 2015



Pan Mersey
Area Prescribing Committee

COMBINATION PRODUCTS, ORAL

**B
L
A
C
K**

The Pan Mersey Area Prescribing Committee does not recommend the routine prescribing of ORAL COMBINATION PRODUCTS that are available as the separate constituents.

The Pan Mersey Area Prescribing Committee does not recommend the routine prescribing of ORAL COMBINATION PRODUCTS that are available as the separate constituents for the following reasons:

- > individual medicines doses cannot be tailored
- > few combination products have a non-proprietary name which leads to the use of brand names or the creation of compound names which do not appear in the BNF. The use of brand names or created compound names increases the risk of prescribing errors.
- > in the event of an allergic or adverse drug reaction to the combination product then it would be difficult to ascertain the drug molecule which has caused this reaction

There are a number of exceptions to this advice and these are listed below:

- > Treatments for Parkinson's disease
- > Treatments for tuberculosis (TB)
- > Treatments for human immunodeficiency virus (HIV) infection
- > Treatments for cancer
- > Hormone replacement therapy (HRT)
- > Oral contraceptives
- > Calcium and vitamin D preparations

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.